Although Amgen is the world’s biggest biotechnology company, the drug maker has been mostly absent from one of the industry’s biggest and fastest-growing markets: cancer drugs. It took a big step to fix that on Sunday, agreeing to buy Onyx Pharmaceuticals for about $10.4 billion in cash to gain access to the company’s three anticancer treatments. Under the terms of Sunday’s deal, Amgen will offer $125 a share in cash through a tender offer for Onyx’s shares.
Help employers find you! Check out all the jobs and post your resume.
